Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst
1. PEN reported Q1 2025 earnings that exceeded expectations significantly. 2. Sales reached $324.1 million, beating forecasts and growing 16.3% year-over-year. 3. Thrombectomy products revenue climbed 20.7%, with U.S. sales up 25.0%. 4. Analysts raised price targets, indicating strong confidence in PEN's growth. 5. Company forecasts reaffirmed despite macroeconomic considerations impacting other sectors.